Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)

Next Previous
X
Search
Trial Profile

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HuMax IL8 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary) ; Celecoxib
  • Indications Adenocarcinoma; Colon cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms NICHE

    • Most Recent Events

    • 16 Apr 2024 The study was amended in Nov 2022 to add cohort 5 and 6, both in which patients will receive nivolumab plus relatlimab (anti-LA G3).
    • 16 Apr 2024 According to ClinicalTrials.gov record, accrual for cohort 4 was reached in July 2023. In April 2024, accrual for cohort 6 was reached. Per April 2024 only cohort 5 is open for recruitment.
    • 24 Oct 2023 According to Results presented at the 48th European Society for Medical Oncology Congress, accrual is currently ongoing in stage 2, in which an additional 40 patients will be treated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top